Latham & Watkins Advises Rhythm Pharmaceuticals in Non-Dilutive Revenue Interest Financing

A multidisciplinary team advises the clinical stage biopharmaceutical company on the royalty financing with Healthcare Royalty Partners for up to US$100 million.

June 17, 2022

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, has announced that it has entered into a Revenue Interest Financing Agreement, with HealthCare Royalty Partners for a total investment amount of up to US$100 million. Rhythm intends to use the proceeds to support global commercialization efforts for IMCIVREE® (setmelanotide) and ongoing clinical development to improve outcomes for people suffering from these rare genetic diseases.

Latham & Watkins represents Rhythm Pharmaceuticals, Inc. in the transaction with a transactional team led by Bay Area partner Haim Zaltzman, Boston partner Pete Handrinos, Bay Area partner Dan Van Fleet, with Bay Area associate Trevor Church and Los Angeles associate Rychelle Andersen. Advice was also provided on corporate and capital markets matters by New York partners Jenna Cooper and Reza Mojtabaee-Zamani, with London associate Nicole McNeil and New York associates Hamna Ahmad and Eric Rice; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, Brussels partner Eveline Van Keymeulen, Bay Area partner Heather Deixler and Bay Area counsel Betty Pang, with Washington, D.C. associate Chad Jennings; on intellectual property matters by Bay Area partners Judith Hasko and Jekkie Kim; on benefits and compensation matters by Bay Area partner Maj Vaseghi; and on tax matters by Bay Area partner Katharine Moir.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.